To combat the growing number of antibiotic-resistant bacteria new therapeutic strategies are needed. Our proposal aims to create novel therapeutics that can interfere with the adhesion of pathogenic bacteria to carbohydrate ligands present on target tissues. For many bacteria this event is the first and crucial step that leads to an infection. Since multiple copies of the bacterial receptors are present the optimal strategy is to use multiple copies of the carbohydrate, i. e. multivalency. This strategy can lead to dramatically enhanced binding compared to monovalent interactions. The specific carbohydrates will be synthesised chemically and will be coupled to novel multivalent backbone molecules. The molecules are evaluated in various adhesion assays and their applicability will be evaluated with relevant animal model studies. Our target pathogenic bacteria are H. pylori, E. coli, and S. suis.
Funding SchemeCSC - Cost-sharing contracts
20520 Turku / Abo